Holen Sie sich die Stockscreener-App
44.75
0.78%
-0.35
Vorhandelsmarkt:
45.55
0.80
+1.79%
Schlusskurs vom Vortag:
$45.10
Offen:
$45.8
24-Stunden-Volumen:
1.46M
Relative Volume:
1.53
Marktkapitalisierung:
$329.23M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-121.02M
KGV:
-3.9742
EPS:
-11.26
Netto-Cashflow:
$-114.09M
1W Leistung:
+1.24%
1M Leistung:
+38.29%
6M Leistung:
+40.28%
1J Leistung:
-20.57%
1-Tages-Spanne:
$41.64
$45.82
1-Wochen-Bereich:
$41.64
$50.40
52-Wochen-Spanne:
$7.31
$130.00
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Firmenname
Tonix Pharmaceuticals Holding Corp
Sektor
Branche
Telefon
212-980-9155
Adresse
26 MAIN STREET, SUITE 101, CHATHAM, NY
Vergleichen Sie TNXP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
44.75 | 325.19M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-04-18 | Eingeleitet | Noble Capital Markets | Outperform |
| 2019-04-18 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2017-08-18 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2016-09-07 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-02-17 | Bestätigt | Oppenheimer | Outperform |
| 2015-11-04 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-06-12 | Eingeleitet | Oppenheimer | Outperform |
| 2015-02-17 | Bestätigt | ROTH Capital | Buy |
| 2014-09-29 | Bestätigt | ROTH Capital | Buy |
Alle ansehen
Tonix Pharmaceuticals Holding Corp Aktie (TNXP) Neueste Nachrichten
Tonix Pharmaceuticals Holding Corp. Stock Analysis and ForecastPhenomenal wealth increase - jammulinksnews.com
Is Tonix Pharmaceuticals Holding Corp. a good long term investmentTriple-digit returns - jammulinksnews.com
Tonix Pharmaceuticals shares rise 2.00% premarket after launching Move Fibro Forward campaign for fibromyalgia awareness. - AInvest
Tonix Pharmaceuticals Announces the Launch of the “Move - GlobeNewswire
Tonix Pharma Launches Move Fibro Forward Campaign - TipRanks
Tonix Tackles 15-Year Fibromyalgia Treatment Void with Groundbreaking Patient Support Campaign - Stock Titan
What drives Tonix Pharmaceuticals Holding Corp. stock priceFree Stock Market Mentorship - Autocar Professional
What analysts say about Tonix Pharmaceuticals Holding Corp. stockSuperior returns - Autocar Professional
Tonix targets August PDUFA date for Fibromyalgia drug candidate, advances mpox vaccine strategy - Proactive financial news
Tonix Pharma Stock Soars After Roping In Former Celgene Corp Executive Joseph Hand: Retail Gets More Positive - MSN
Are TNXP Shares Ready for a Comeback? - StocksToTrade
Tonix Pharma Plans Sales Force for TNX-102 SL - TipRanks
Tonix Pharmaceuticals ($TNXP) Skyrockets 284% in 2025: Earnings Catalysts.... - Investing.com India
Tonix reports TNX-801 vaccine shows promise against mpox By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals Shares Climb on Encouraging TNX-801 Vaccine Results - MSN
Tonix Pharmaceuticals Announces Presentation of New Data on - GlobeNewswire
Tonix Pharma stock up after data for pain drug (TNXP:NASDAQ) - Seeking Alpha
Tonix Pharmaceuticals stock rises on promising TNX-801 vaccine data By Investing.com - Investing.com India
Tonix Pharmaceuticals stock rises on promising TNX-801 vaccine data - Investing.com Australia
Tonix reports TNX-801 vaccine shows promise against mpox - Investing.com
Tonix Pharma Unveils Promising TNX-801 Vaccine Findings - TipRanks
Revolutionary Mpox and Smallpox Vaccine Achieves 100,000-Fold Safety Improvement with Single-Dose Protection - Stock Titan
Tonix Pharmaceuticals shares rise 1.75% premarket after publishing positive Phase 3 trial results for TNX-102 SL. - AInvest
Tonix Pharmaceuticals Announces On-line Publication of - GlobeNewswire
Tonix Pharmaceuticals' TNX-102 SL: A Breakthrough in Fibromyalgia Treatment and Its Implications for Investors - AInvest
Tonix’s fibromyalgia drug shows positive results in phase 3 trial By Investing.com - Investing.com South Africa
Tonix’s fibromyalgia drug shows positive results in phase 3 trial - Investing.com Australia
Tonix Pharma Publishes Phase 3 Trial Results - TipRanks
Tonix Pharmaceuticals Announces Publication of Positive Phase 3 RESILIENT Trial Data for TNX-102 SL in Fibromyalgia Management - Nasdaq
Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine - Yahoo Finance
Breakthrough Fibromyalgia Treatment Shows Superior Pain Relief in Phase 3 Trial, FDA Decision Looms - Stock Titan
Tonix Pharmaceuticals Announces Efficacy and Safety of Single-Dose TNX-801 Vaccine Against Monkeypox - Quiver Quantitative
Tonix Pharmaceuticals Announces Oral Presentation on Mpox - GlobeNewswire
Breakthrough: New Single-Dose Vaccine Demonstrates 100% Protection Against Deadly Mpox Challenge - Stock Titan
Tonix Pharmaceuticals Announces Peer-Reviewed Publication - GlobeNewswire
Major Cancer Treatment Breakthrough: New Drug Combo Defeats Immunotherapy Resistance in Gastric Cancer - Stock Titan
Tonix Pharmaceuticals Holding Corp.(NasdaqCM: TNXP) added to Russell 3000E Index - MarketScreener
Tonix Pharmaceuticals Joins Elite Russell Indexes Ahead of Major FDA Decision - Stock Titan
Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® Indexes - GlobeNewswire
Tonix Pharmaceuticals Holding Corp.(NasdaqCM: TNXP) added to Russell 2500 Index - MarketScreener
Fibromyalgia drug nearing approval after a 16-year lull - biocentury.com
How To Trade (TNXP) - news.stocktradersdaily.com
Tonix Pharmaceuticals Reports Promising Phase 3 Results for Fibromyalgia Treatment at EULAR 2025 - citybuzz -
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL - GuruFocus
Tonix Pharmaceuticals: Big Risk, Bigger RewardInitiating With A Buy (NASDAQ:TNXP) - Seeking Alpha
Tonix Pharma Presents Data at Rheumatology Congress - TipRanks
Tonix Pharmaceuticals (TNXP) Highlights Fibromyalgia Treatment a - GuruFocus
Tonix Pharmaceuticals (TNXP) Highlights Fibromyalgia Treatment at EULAR 2025 | TNXP Stock News - GuruFocus
Tonix Pharmaceuticals Presented Data and Analyses of - GlobeNewswire
Finanzdaten der Tonix Pharmaceuticals Holding Corp-Aktie (TNXP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):